DALLAS and FORT WORTH, Texas, June 27, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technology platforms, today announced the pricing of an underwritten public offering of $32.4 million of shares of its common stock at a price to the public of $6.75 per share, before deducting underwriting discounts and commissions and other offering expenses payable by Neos. In addition, Neos has granted the underwriters a 30-day option to purchase up to an additional $4.9 million of shares of common stock. This offering is expected to close on June 30, 2017, subject to customary closing conditions.
Cantor Fitzgerald & Co is acting as sole bookrunner for the offering.
About Neos Therapeutics
Neos Therapeutics, Inc. is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODTTM, indicated for the treatment of ADHD in patients 6 years of age and older, and Cotempla XR-ODTTM, indicated for the treatment of ADHD in patients 6 to 17 years old, are the first approved products using the Company’s extended-release (XR)-orally disintegrating tablet (ODT) technology platform. Neos, which is initially focusing on the treatment of ADHD, has filed New Drug Applications with the U.S. Food and Drug Administration for one other branded product candidate that is an XR medication in oral suspension dosage form. In addition, Neos manufactures and markets its generic equivalent of the branded product Tussionex®, an XR oral suspension of hydrocodone and chlorpheniramine indicated for the relief of cough and upper respiratory symptoms of a cold.
